<?xml version="1.0" encoding="UTF-8"?>
<ref id="B130-pharmaceutics-13-00387">
 <label>130.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Goode</surname>
    <given-names>G.A.</given-names>
   </name>
   <name>
    <surname>Wagh</surname>
    <given-names>S.J.</given-names>
   </name>
   <name>
    <surname>Irby</surname>
    <given-names>D.J.</given-names>
   </name>
   <name>
    <surname>Ma</surname>
    <given-names>D.</given-names>
   </name>
   <name>
    <surname>Jacobs</surname>
    <given-names>R.F.</given-names>
   </name>
   <name>
    <surname>Kearns</surname>
    <given-names>G.L.</given-names>
   </name>
   <name>
    <surname>Almoazen</surname>
    <given-names>H.</given-names>
   </name>
  </person-group>
  <article-title>Bioavailability testing of a newly developed clindamycin oral suspension in a pediatric porcine model</article-title>
  <source>Pharm. Dev. Technol.</source>
  <year>2019</year>
  <volume>24</volume>
  <fpage>1038</fpage>
  <lpage>1043</lpage>
  <pub-id pub-id-type="doi">10.1080/10837450.2019.1624771</pub-id>
  <?supplied-pmid 31134840?>
  <pub-id pub-id-type="pmid">31134840</pub-id>
 </element-citation>
</ref>
